Article: Cadence Files For $86M IPO; Osiris Provides Price Range.

Staff Writer

Cadence Pharmaceuticals Inc. filed for its initial public offering, hoping to raise as much as $86 million to support clinical development of its two late-stage candidates targeting pain and infection in hospital settings.

The San Diego-based firm has not yet disclosed the number of shares or share price, and what the company would be able to pull in remains to be seen, as the current environment is downsizing IPOs. In fact, stem cell firm Osiris Therapeutics Inc. on Monday set its share amount and price range that cuts its IPO expectations by half.

Representatives of Cadence, which anticipates a Nasdaq listing ticker symbol of ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!